SCHEMBL3694010

SCHEMBL3694010

O=C(Cc1ccccc1)NCc1nc2c(C(F)(F)F)cc(-c3ccoc3)cn2c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NAT1 P18440 1/20 0.36
MALT1 Q9UDY8 1/20 0.35
CNR2 P34972 1/20 0.35
GRIA1 P42261 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA3 P42263 1/20 0.35
GRIA4 P48058 1/20 0.35
ALDH1A1 P00352 4/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
SUCNR1 Q9BXA5 1/20 0.34
SERPINE1 P05121 1/20 0.34
SRC P12931 1/20 0.34
GLA P06280 1/20 0.34
WDR5 P61964 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3696074 0.87 RAB9A (0.44) PKMALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL3690075 0.84 NPC1 (0.40) PKMALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL3696257 0.82 ALDH1A1 (0.40) NAT1MALT1CNR2GRIA1GRIA2
SCHEMBL3695420 0.82 CACNA1H (0.38) PKMRXFP1LMNATRPV1
SCHEMBL3686846 0.80 SIGMAR1 (0.36) PKMRXFP1NAT1CNR2ALDH1A1
SCHEMBL3790970 0.78 ALDH1A1 (0.46) ALDH1A1LMNARAB9ANPC1SUCNR1
SCHEMBL3689147 0.77 CSNK2A1 (0.36) SMN1; SMN2
SCHEMBL1583247 0.76 ERN1 (0.40) PKMRXFP1SERPINE1MAPT
SCHEMBL3694168 0.76 PKM (0.41) PKMRXFP1ALDH1A1LMNASERPINE1
SCHEMBL7501784 0.76 POLB (0.36) PKMRXFP1LMNASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 PKM 2286/4885RXFP1 4676/4885NAT1 83/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 PKM 2286/4885RXFP1 4676/4885NAT1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.